025sek
-0,2 %
Date:2024-04-26Time:17:29:00Latest report:Q4-2023List:SpotlightTicker:DICOT
Market Cap:203 msekEnterprise Value:155 msekNet Sales:- msekEarnings:-44,2 msekEmployees:0ISIN:SE0011178458

Ratios

10-year key figure history for Dicot turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Dicot with index and moving average MA50 and MA200.

Stockprice:0,25
MA50:0,21
MA200:0,19
Price/MA200:30,3 %
RSI (14):60,6
Price/MA50:16,5 %

Description

Dicot's business concept is to develop the drug candidate Libiguin as a drug for the treatment of sexual dysfunction. The development takes place under its own auspices up to clinical phases. It is the company's intention to subsequently enter into strategic alliances at appropriate times, or alternatively carry out a trade sale, with established larger pharmaceutical companies in order to be able to introduce Libiguin on the world market.

Pharmaceuticals